Dietary supplementation with probiotics during late pregnancy: outcome on vaginal microbiota and cytokine secretion

Beatrice Vitali, Federica Cruciani, Maria Elisabetta Baldassarre, Teresa Capursi, Enzo Spisni, Maria Chiara Valerii, Marco Candela, Silvia Turroni, Patrizia Brigidi, Beatrice Vitali, Federica Cruciani, Maria Elisabetta Baldassarre, Teresa Capursi, Enzo Spisni, Maria Chiara Valerii, Marco Candela, Silvia Turroni, Patrizia Brigidi

Abstract

Background: The vaginal microbiota of healthy women consists of a wide variety of anaerobic and aerobic bacterial genera and species dominated by the genus Lactobacillus. The activity of lactobacilli helps to maintain the natural healthy balance of the vaginal microbiota. This role is particularly important during pregnancy because vaginal dismicrobism is one of the most important mechanisms for preterm birth and perinatal complications. In the present study, we characterized the impact of a dietary supplementation with the probiotic VSL#3, a mixture of Lactobacillus, Bifidobacterium and Streptococcus strains, on the vaginal microbiota and immunological profiles of healthy women during late pregnancy.

Results: An association between the oral intake of the probiotic VSL#3 and changes in the composition of the vaginal microbiota of pregnant women was revealed by PCR-DGGE population profiling. Despite no significant changes were found in the amounts of the principal vaginal bacterial populations in women administered with VSL#3, qPCR results suggested a potential role of the probiotic product in counteracting the decrease of Bifidobacterium and the increase of Atopobium, that occurred in control women during late pregnancy. The modulation of the vaginal microbiota was associated with significant changes in some vaginal cytokines. In particular, the decrease of the anti-inflammatory cytokines IL-4 and IL-10 was observed only in control women but not in women supplemented with VSL#3. In addition, the probiotic consumption induced the decrease of the pro-inflammatory chemokine Eotaxin, suggesting a potential anti-inflammatory effect on the vaginal immunity.

Conclusion: Dietary supplementation with the probiotic VSL#3 during the last trimester of pregnancy was associated to a modulation of the vaginal microbiota and cytokine secretion, with potential implications in preventing preterm birth.

Trial registration: ClinicalTrials.gov NCT01367470.

Figures

Figure 1
Figure 1
PCR-DGGE analysis with universal primers for bacteria. Analysis was conducted on the vaginal samples collected at 33rd (W33) and 37th (W37) week of gestation from 15 women supplemented with the probiotic VSL#3 [(P) N. 1–15] and 12 control women [(C) N. 16–27]. N: woman number; W: week of gestation; T: type of supplementation. (A) PCR-DGGE fingerprints. M, external reference marker. (B) Dendrogram of the DGGE profiles shown in panel A. Pearson correlation was used to calculate the similarity in DGGE profiles.
Figure 2
Figure 2
PCR-DGGE analysis with Lactobacillus-specific primers. Analysis was conducted on the vaginal samples collected at 33rd (W33) and 37th (W37) week of gestation from 15 women supplemented with the probiotic VSL#3 [(P) N. 1–15] and 12 control women [(C) N. 16–27]. N: woman number; W: week of gestation; T: type of supplementation. (A) PCR-DGGE fingerprints. M, external reference marker. Band L16 corresponds to L. helveticus (GenBank accession number: AB571603) (B) Dendrogram of the DGGE profiles shown in panel A. Pearson correlation was used to calculate the similarity in DGGE profiles.
Figure 3
Figure 3
qPCR evaluation of Lactobacillus(A),Bifidobacterium(B),Atopobium(C)andPrevotella(D). Analysis was performed on vaginal samples collected at 33rd (W33) and 37th (W37) week of gestation from pregnant women supplemented (P) and not supplemented (C) with VSL#3. Data are expressed as ng of DNA of the target genus per μg of total bacterial DNA extracted from the vaginal sample. The diagrams show the mean values with error bars representing the standard deviations.
Figure 4
Figure 4
Cytokines and chemokines whose concentration significantly changed during the study period (P<0.05). P, probiotic group; C, control group; W33, 33rd gestational week (black colour); W37, 37th gestational week (grey colour). Cytokine or chemokine names are reported in x-axis. Data are expressed as pg of the target cytokine or chemokine per μg of total proteins present in the vaginal sample (y-axis). The diagrams show means with error bars representing the standard deviations.
Figure 5
Figure 5
Women registering significant variations in total levels of immune-mediators. P, probiotic group; C, control group; W33, 33rd gestational week (black colour); W37, 37th gestational week (grey colour). Identification numbers of women registering significant variations are reported in x-axis. Data are expressed as pg of total immune-mediators per μg of total vaginal proteins (y-axis). The diagrams show means with error bars representing the standard deviations.

References

    1. Lidbeck A, Nord CE. Lactobacilli and the normal human anaerobic microflora. Clin Infect Dis. 1993;16(Suppl 4):181–187.
    1. Donati L, Di Vico A, Nucci M, Quagliozzi L, Spagnuolo T, Labianca A, Bracaglia M, Ianniello F, Caruso A, Paradisi G. Vaginal microbial flora and outcome of pregnancy. Arch Gynecol Obstet. 2010;281:589–600. doi: 10.1007/s00404-009-1318-3.
    1. Mattison DR, Damus K, Fiore E, Petrini J, Alter C. Preterm delivery: a public health perspective. Paediatr Perinat Epidemiol. 2001;15(Suppl 2):7–16.
    1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371:75–84. doi: 10.1016/S0140-6736(08)60074-4.
    1. Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, Cotch MF, Edelman R, Pastorek JG, Rao AV, McNellis D, Regan JA, Carey JC, Klebanoff MA. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The vaginal infections and prematurity study group. N Engl J Med. 1995;333:1737–1742. doi: 10.1056/NEJM199512283332604.
    1. McGregor JA, French JI. Bacterial vaginosis in pregnancy. Obstet Gynecol Surv. 2000;55(5 Suppl 1):1–19.
    1. Beigi RH, Yudin MH, Cosentino L, Meyn LA, Hillier SL. Cytokines, pregnancy, and bacterial vaginosis: comparison of levels of cervical cytokines in pregnant and nonpregnant women with bacterial vaginosis. J Infect Dis. 2007;196:1355–1360. doi: 10.1086/521628.
    1. Mattsby-Baltzer I, Platz-Christensen JJ, Hosseini N, Rosén P. IL-1beta, IL-6, TNFalpha, fetal fibronectin, and endotoxin in the lower genital tract of pregnant women with bacterial vaginosis. Acta Obstet Gynecol Scand. 1998;77:701–706. doi: 10.1080/j.1600-0412.1998.770701.x.
    1. Norwitz ER, Robinson JN, Challis JR. The control of labor. N Engl J Med. 1999;341:660–666. doi: 10.1056/NEJM199908263410906.
    1. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF, Petraglia F. Inflammation and pregnancy. Reprod Sci. 2009;16:206–215. doi: 10.1177/1933719108329095.
    1. Houben ML, Nikkels PG, van Bleek GM, Visser GH, Rovers MM, Kessel H, de Waal WJ, Schuijff L, Evers A, Kimpen JL, Bont L. The association between intrauterine inflammation and spontaneous vaginal delivery at term: a cross-sectional study. PLoS One. 2009;4:e6572. doi: 10.1371/journal.pone.0006572.
    1. Dubicke A, Fransson E, Centini G, Andersson E, Byström B, Malmström A, Petraglia F, Sverremark-Ekström E, Ekman-Ordeberg G. Pro-inflammatory and anti-inflammatory cytokines in human preterm and term cervical ripening. J Reprod Immunol. 2010;84:176–185. doi: 10.1016/j.jri.2009.12.004.
    1. FAO/WHO. Guidelines for the evaluation of probiotics in food. Food and Agriculture Organization of United Nations and World Health Organization Working Group report, London, Ontario; 2002.
    1. Reid G, Bocking A. The potential for probiotics to prevent bacterial vaginosis and preterm labor. Am J Obstet Gynecol. 2003;189:1202–1208. doi: 10.1067/S0002-9378(03)00495-2.
    1. Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, Bruce AW. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol. 2003;35:131–134. doi: 10.1016/S0928-8244(02)00465-0.
    1. Reid G, Anukam K, James VI, van der Mei HC, Heineman C, Busscher HJ, Bruce AW. Oral probiotics for maternal and newborn health. J Clin Gastroenterol. 2005;39:353–354. doi: 10.1097/01.mcg.0000159268.58480.02.
    1. Rautava S, Kalliomäki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol. 2002;109:119–121. doi: 10.1067/mai.2002.120273.
    1. Huurre A, Laitinen K, Rautava S, Korkeamäki M, Isolauri E. Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization: a double-blind placebo-controlled study. Clin Exp Allergy. 2008;38:1342–1348. doi: 10.1111/j.1365-2222.2008.03008.x.
    1. Zhou X, Bent SJ, Schneider MG, Davis CC, Islam MR, Forney LJ. Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods. Microbiology. 2004;150:2565–2573. doi: 10.1099/mic.0.26905-0.
    1. Hyman RW, Fukushima M, Diamond L, Kumm J, Giudice LC, Davis RW. Microbes on the human vaginal epithelium. Proc Natl Acad Sci U S A. 2005;102:7952–7957. doi: 10.1073/pnas.0503236102.
    1. Sundquist A, Bigdeli S, Jalili R, Druzin ML, Waller S, Pullen KM, El-Sayed YY, Taslimi MM, Batzoglou S, Ronaghi M. Bacterial flora-typing with targeted, chip-based Pyrosequencing. BMC Microbiol. 2007;7:108. doi: 10.1186/1471-2180-7-108.
    1. Vitali B, Pugliese C, Biagi E, Candela M, Turroni S, Bellen G, Donders GG, Brigidi P. Dynamics of vaginal bacterial communities in women developing bacterial vaginosis, candidiasis, or no infection, analyzed by PCR-denaturing gradient gel electrophoresis and real-time PCR. Appl Environ Microbiol. 2007;73:5731–5741. doi: 10.1128/AEM.01251-07.
    1. Oakley BB, Fiedler TL, Marrazzo JM, Fredricks DN. Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosis. Appl Environ Microbiol. 2008;74:4898–4909. doi: 10.1128/AEM.02884-07.
    1. Kim TK, Thomas SM, Ho M, Sharma S, Reich CI, Frank JA, Yeater KM, Biggs DR, Nakamura N, Stumpf R, Leigh SR, Tapping RI, Blanke SR, Slauch JM, Gaskins HR, Weisbaum JS, Olsen GJ, Hoyer LL, Wilson BA. Heterogeneity of vaginal microbial communities within individuals. J Clin Microbiol. 2009;47:1181–1189. doi: 10.1128/JCM.00854-08.
    1. Burton JP, Cadieux PA, Reid G. Improved understanding of the bacterial vaginal microbiota of women before and after probiotic instillation. Appl Environ Microbiol. 2003;69:97–101. doi: 10.1128/AEM.69.1.97-101.2003.
    1. Devillard E, Burton JP, Reid G. Complexity of vaginal microflora as analyzed by PCR denaturing gradient gel electrophoresis in a patient with recurrent bacterial vaginosis. Infect Dis Obstet Gynecol. 2005;13:25–31. doi: 10.1155/2005/607474.
    1. De Backer E, Verhelst R, Verstraelen H, Alqumber MA, Burton JP, Tagg JR, Temmerman M, Vaneechoutte M. Quantitative determination by real-time PCR of four vaginal Lactobacillus species. Gardnerella vaginalis and Atopobium vaginae indicates an inverse relationship between L. gasseri and L. iners. BMC Microbiol. 2007;7:115. doi: 10.1186/1471-2180-7-115.
    1. Biagi E, Vitali B, Pugliese C, Candela M, Donders GG, Brigidi P. Quantitative variations in the vaginal bacterial population associated with asymptomatic infections: a real-time polymerase chain reaction study. Eur J Clin Microbiol Infect Dis. 2009;28:281–285. doi: 10.1007/s10096-008-0617-0.
    1. El Aila NA, Tency I, Claeys G, Verstraelen H, Saerens B, Santiago GL, De Backer E, Cools P, Temmerman M, Verhelst R, Vaneechoutte M. Identification and genotyping of bacteria from paired vaginal and rectal samples from pregnant women indicates similarity between vaginal and rectal microflora. BMC Infect Dis. 2009;9:167. doi: 10.1186/1471-2334-9-167.
    1. Guandalini S, Magazzù G, Chiaro A, La Balestra V, Di Nardo G, Gopalan S, Sibal A, Romano C, Canani RB, Lionetti P, Setty M. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010;51:24–34. doi: 10.1097/MPG.0b013e3181ca4d95.
    1. Brigidi P, Vitali B, Swennen E, Altomare L, Rossi M, Matteuzzi D. Specific detection of Bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction. Syst Appl Microbiol. 2000;23:391–399. doi: 10.1016/S0723-2020(00)80070-3.
    1. Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro TT, Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. PNAS. 2010;107:454–459. doi: 10.1073/pnas.0910307107.
    1. Stoyancheva GD, Danova ST, Boudakov IY. Molecular identification of vaginal lactobacilli isolated from Bulgarian women. Antonie Van Leeuwenhoek. 2006;90:201–210. doi: 10.1007/s10482-006-9072-z.
    1. Törnblom SA, Klimaviciute A, Byström B, Chromek M, Brauner A, Ekman-Ordeberg G. Non-infected preterm parturition is related to increased concentrations of IL-6, IL-8 and MCP-1 in human cervix. Reprod Biol Endocrinol. 2005;3:39. doi: 10.1186/1477-7827-3-39.
    1. Fortunato SJ, Menon R, Lombardi SJ. Interleukin-10 and transforming growth factor-beta inhibit amniochorion tumor necrosis factor-alpha production by contrasting mechanisms of action: therapeutic implications in prematurity. Am J Obstet Gynecol. 1997;177:803–809. doi: 10.1016/S0002-9378(97)70272-2.
    1. Brown NL, Alvi SA, Elder MG, Bennett PR, Sullivan MH. The regulation of prostaglandin output from term intact fetal membranes by anti-inflammatory cytokines. Immunology. 2000;99:124–133. doi: 10.1046/j.1365-2567.2000.00942.x.
    1. Athayde N, Romero R, Maymon E, Gomez R, Pacora P, Araneda H, Yoon BH. A role for the novel cytokine RANTES in pregnancy and parturition. Am J Obstet Gynecol. 1999;181:989–994. doi: 10.1016/S0002-9378(99)70337-6.
    1. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med. 1996;2:449–456. doi: 10.1038/nm0496-449.
    1. Walter J, Tannock GW, Tilsala-Timisjarvi A, Rodtong S, Loach DM, Munro K, Alatossava T. Detection and identification of gastrointestinal Lactobacillus species by using denaturing gradient gel electrophoresis and species-specific PCR primers. Appl Environ Microbiol. 2000;66:297–303. doi: 10.1128/AEM.66.1.297-303.2000.
    1. Walter J, Hertel C, Tannock GW, Lis CM, Munro K, Hammes WP. Detection of Lactobacillus, Pediococcus, Leuconostoc, and Weissella species in human feces by using group-specific PCR primers and denaturing gradient gel electrophoresis. Appl Environ Microbiol. 2001;67:2578–2585. doi: 10.1128/AEM.67.6.2578-2585.2001.
    1. Bassam BJ, Caetano-Anollés G, Gresshoff PM. Fast and sensitive silver staining of DNA in polyacrylamide gels. Anal Biochem. 1991;196:80–83. doi: 10.1016/0003-2697(91)90120-I.
    1. Heilig HGHJ, Zoetendal EG, Vaughan EE, Marteau P, Akkermans AD, de Vos WM. Molecular diversity of Lactobacillus spp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA. Appl Environ Microbiol. 2002;68:114–123. doi: 10.1128/AEM.68.1.114-123.2002.
    1. Kok RG, de Waal A, Schut F, Welling GW, Weenk G, Hellingwerf KJ. Specific detection and analysis of a probiotic Bifidobacterium strain in infant feces. Appl Environ Microbiol. 1996;62:3668–3672.
    1. Tilsala-Timisjärvi A, Alatossava T. Development of oligonucleotide primers from the 16S-23S rRNA intergenic sequences for identifying different dairy and probiotic lactic acid bacteria by PCR. Int J Food Microbiol. 1997;35:49–56. doi: 10.1016/S0168-1605(97)88066-X.
    1. Zariffard MR, Saifuddin M, Sha BE, Spear GT. Detection of bacterial vaginosis-related organisms by real-time PCR for Lactobacilli, Gardnerella vaginalis and Mycoplasma hominis . FEMS Immunol Med Microbiol. 2002;34:277–281. doi: 10.1111/j.1574-695X.2002.tb00634.x.
    1. Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R. Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol. 2004;70:7220–7228. doi: 10.1128/AEM.70.12.7220-7228.2004.
    1. Matsuki T, Watanabe K, Fujimoto J, Miyamoto Y, Takada T, Matsumoto K, Oyaizu H, Tanaka R. Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces. Appl Environ Microbiol. 2002;68:5445–5451. doi: 10.1128/AEM.68.11.5445-5451.2002.
    1. Rinttilä T, Kassinen A, Malinen E, Krogius L, Palva A. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol. 2004;97:1166–1177. doi: 10.1111/j.1365-2672.2004.02409.x.
    1. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods. 2000;243:243–255. doi: 10.1016/S0022-1759(00)00238-6.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe